68Ga-奥曲肽PET/CT显像患者对周围人群产生的有效剂量的估算

目的 估算68Ga-奥曲肽PET/CT显像患者对周围人群产生的有效剂量。 方法 采用简单随机抽样的方法选取2021年10至12月于北京大学肿瘤医院接受68Ga-奥曲肽PET/CT显像的20例患者进行前瞻性研究，其中男性15例、女性5例，年龄30~68（49.0±12.2）岁。在患者静脉注射68Ga-奥曲肽0 h后，使用辐射监测剂量仪测量距患者1.0 m处的空气吸收剂量率，注射1.0 h后测量距患者0.3 m处的空气吸收剂量率，注射1.5 h后测量距患者0.3、0.5、1.0和1.5 m处的空气吸收剂量率。依据美国国家辐射防护和测量委员会第155号报告提出的人类社会活动模式，采用积分法估算68Ga-奥曲肽PET/CT显像患者对周围人群产生的有效剂量。 结果 注射68Ga-奥曲肽0 h后，距患者1.0 m处的空气吸收剂量率为12.97~33.67 （20.24±6.57） μSv/h；注射1.0 h后，距患者0.3 m处的空气吸收剂量率为32.73~57.69（48.98±6.20） μSv/h；注射1.5 h后，距患者0.3、0.5、1.0、1.5 m处的空气吸收剂量率分别为24.04~42.39（35.98±4.56） μSv/h、11.83~28.83（20.70±4.55） μSv/h、5.17~13.42（8.07±2.61） μSv/h、1.51~7.01（3.75±1.72） μSv/h。与68Ga-奥曲肽显像患者白天接触的家庭成员受照的有效剂量为8.22~21.33（12.83±4.15） μSv，夜间同床共睡的家庭成员受照的有效剂量为38.92~68.62（58.25±7.38） μSv，单位同事受照的有效剂量为8.37~21.73（13.06±4.23） μSv，同车邻座乘客受照的有效剂量为32.97~58.15（49.36±6.26） μSv。每接触一例患者，操作人员受照的有效剂量为2.66~4.69（3.98±0.50） μSv，陪护护士受照的有效剂量为9.70~25.17（15.13±4.90） μSv。 结论 68Ga-奥曲肽PET/CT显像患者对周围人群产生的有效剂量远低于国家标准规定的有效剂量限值。

Estimation of the effective dose of 68Ga-Octreotide PET/CT imaging patients to the surrounding population

Objective To estimate the effective dose of 68Ga-Octreotide PET/CT imaging patients to the surrounding population. Methods Twenty patients (15 males and 5 females, aged 30–68 (49.0±12.2) years) who received 68Ga-Octreotide PET/CT imaging at Peking University Cancer Hospital from October 2021 to December 2021 were randomly selected. After intravenous injection of 68Ga-Octreotide, the air absorbed dose rate at 1 m away from the patient was measured by radiation monitoring dosimeter 0 h later, at 0.3 m away from the patient 1.0 h later, and at 0.3, 0.5, 1.0, and 1.5 m away from the patient 1.5 h later. Based on the patterns of human social activity proposed by the National Commission for Radiological Protection and Measurement No.155 report, integral method was used to estimate the effective dose of 8Ga-Octreotide PET/CT imaging patients to the surrounding population. Results Immediately after the injection of 68Ga-Octreotide, the air absorbed dose rate at 1.0 m away from the patient was 12.97–33.67 (20.24±6.57) μSv/h. At 1.0 h later, the air absorbed dose rate at 0.3 m away from the patient was 32.73–57.69(48.98±6.20) μSv/h. At 1.5 h later, the air absorbed dose rates at 0.3, 0.5, 1.0, and 1.5 m away from the patient were 24.04–42.39 (35.98±4.56), 11.83–28.83 (20.70±4.55), 5.17–13.42 (8.07±2.61), and 1.51–7.01 (3.75±1.72) μSv/h, respectively. The estimated effective doses were as follows: 8.22–21.33 (12.83±4.15) μSv to a family member exposed to the patients at the daytime; 38.92–68.62 (58.25±7.38) μSv to a family member who shared a bed at night with the patients; 8.37–21.73 (13.06±4.23) μSv to a colleague; and 32.97–58.15 (49.36±6.26) μSv to an adjacent passenger. The radiation doses per 68Ga-Octreotide PET/CT imaging patients was estimated to be 2.66–4.69 (3.98±0.50) μSv to the operator and 9.70–25.17(15.13±4.90) μSv to the attending nurses. Conclusion The effective dose of 68Ga Octreotide PET/CT imaging patients to the surrounding population is far lower than the effective dose limit specified in the national standard.